التفاصيل البيبلوغرافية
| العنوان: |
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials. |
| المؤلفون: |
Monami, Matteo1 mmonami@libero.it, Cremasco, Francesco2, Lamanna, Caterina2, Colombi, Claudia2, Desideri, Carla Maria1, Iacomelli, Iacopo1, Marchionni, Niccolò1, Mannucci, Edoardo1,2,3 |
| المصدر: |
Experimental Diabetes Research. 2011, Special section p1-10. 10p. 1 Diagram, 3 Charts, 1 Graph. |
| مصطلحات موضوعية: |
*TYPE 2 diabetes, *GLUCAGON-like peptide-1 receptor, *GLUCAGON-like peptide-1 agonists, *META-analysis, *CLINICAL trials |
| مستخلص: |
Objective. Data from randomized clinical trials with metabolic outcomes can be used to address concerns about potential issues of cardiovascular safety for newer drugs for type 2 diabetes. This meta-analysis was designed to assess cardiovascular safety of GLP-1 receptor agonists. Design and Methods. MEDLINE, Embase, and Cochrane databases were searched for randomized trials of GLP-1 receptor agonists (versus placebo or other comparators) with a duration ≥12 weeks, performed in type 2 diabetic patients. Mantel-Haenszel odds ratio with 95% confidence interval (MH-OR) was calculated for major cardiovascular events (MACE), on an intention-to-treat basis, excluding trials with zero events. Results. Out of 36 trials, 20 reported at least one MACE. The MH- OR for all GLP-1 receptor agonists was 0.74 (0.50-1.08), P = .12 (0.85 (0.50-1.45), P = .55, and 0.69 (0.40-1.22), P = .20, for exenatide and liraglutide, resp.). Corresponding figures for placebo-controlled and active comparator studies were 0.46 (0.25-0.83), P = .009, and 1.05 (0.63-1.76), P = .84, respectively. Conclusions. To date, results of randomized trials do not suggest any detrimental effect of GLP-1 receptor agonists on cardiovascular events. Specifically designed longer-term trials are needed to verify the possibility of a beneficial effect. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder